Cuban CRO-alternative must continue standards evolution

By Nick Taylor

- Last updated on GMT

Related tags Clinical trials Contract research organization Clinical trial

The Cuban clinical trial centre must continue evolving to keep pace with the multinational CROs to which it provides an alternative.

Established in 1991 to improve research success, the National Clinical Trials Coordinating Center (CENCEC) operates as a Cuban alternative to contract research organisations (CRO). Mirroring CROs, services offered by CENCEC include trial design, data management and analysis.

From the Center’s creation, it was designed to offer a complete range of services, usually only available from large global or multinational contract research centres​”, according researchers writing in MEDDIC Review​.

Now, as before, the challenge is to continue developing: The goal is: “To ensure a clinical evaluation process that meets international standards​. Growing demands on the part of industry challenge the organisation to seek efficient solutions to reach goals unimagined 18 years ago​.”


In some respects CENCEC differs from multinational CROs. “Some of CENCEC’s distinguishing characteristics include its national scope, its combination of scientific services with academic and health research, and continued human resource development​”, say the researchers.

The research paper details the development of CENCEC since it was formed in 1991 to improve clinical trials. From 1992 to 2008 CENCEC conducted 103 clinical trials on behalf of 24 sponsors.

A complete picture of the number of trials, clinical sites, investigators and patient recruitment is shown in the table below. Of the 103 trials, 62 per cent were for biotech products and 18 per cent were for small molecules. Medical devices and natural products account for most other trials.

Overseas biotech

The large proportion of biotech trials is reflected in the list of sponsors, shown below. Another feature of the list is the low number of trials conducted as part of international studies. The report attributes this to CENCEC fulfilling its core mission of evaluating Cuban biopharm products.

Biotech in Cuba has, to a large extent, been cut off from much of the world. However, last month the US lifted some restrictions​ to allow greater educational and academic interaction between the two countries.

Related news

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more